ATA Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (29)

Latest Posts

About This Stock More About This Stock
S June Update: Psychedelic Compounds-Based Drug Stocks Index Up 8%; Down 55% YTD
Article By: Lorimer Wilson
Friday, July 1, 2022 10:50 AM EDT
The psychedelic Compounds-Based Drug Stocks Index was up 7.7% in June but is still down 54.9% YTD.
In this article: ATAI, MNMD, CMPS, ZYNE, SEEL, GHRS, ALID, CYBN
Read
S Rebalanced Psychedelic Compounds-Based Drug Stocks Index Down 52.7% YTD
Article By: Lorimer Wilson
Monday, June 27, 2022 2:56 PM EDT
The Psychedelic Compounds-Based Drug Stocks Index is down 52.7% YTD and down 75.9% from its highest point in 2021.
In this article: MNMD, ATAI, CYBN, CMPS, GHRS, ZYNE, SEEL, ALID
Read
S Psychedelic Compounds-Based Stocks Continue To Decline
Article By: Lorimer Wilson
Monday, May 30, 2022 2:30 AM EDT
Our index tracks 6 of the largest clinical-stage startups, which have an average market capitalization of $65.5M and an average stock price of $0.69/share.
In this article: ATAI, MNMD, CMPS, ZYNE, SEEL, GHRS, CYBN, FTRP
Read
S Psychedelic Compounds-Based Stocks Index Imploding
Article By: Lorimer Wilson
Saturday, May 14, 2022 8:00 AM EDT
Our index of Psychedelic Compounds-Based Drug Stocks tracking clinical-stage startups still in R&D is down 60% YTD; it's -78% from its 2021 high.
In this article: ATAI, MNMD, CMPS, ZYNE, GHRS, ALID, CYBN
Read
S Psychedelic Stocks Continue To Decline In May
Article By: Lorimer Wilson
Sunday, May 8, 2022 12:01 AM EDT
The 10 companies in our Psychedelic Compounds-Based Drug Stocks Index are clinical-stage startups still in the product research and development of novel compounds with no products and no revenue.
In this article: ATAI, MNMD, CMPS, ZYNE, GHRS, CYBN, FTRP
Read

Latest Tweets for $ATAI

No tweets yet!

PARTNER HEADLINES